-
Intestinal Stretch, Weight Loss, and Satiety
2026-08-26
The reference study shows that intestinal stretch is an independent regulator of acute food intake and oral glucose tolerance, and that obesity weakens this response. Both dietary and surgical weight loss restored stretch-induced satiety signaling, highlighting a mechanical gut–brain pathway that complements, but does not depend on, classical GLP-1 signaling.
-
Validated HPLC Analysis of Trelagliptin Succinate
2026-08-26
This 2018 European Journal of Pharmaceutical Sciences study developed and validated a stability-indicating HPLC method for trelagliptin succinate and eight potential process-related impurities. Its combination of chromatographic separation, forced-degradation testing, and UHPLC–high-resolution tandem mass spectrometry provides a practical framework for pharmaceutical quality control and reproducible diabetes mellitus research workflows.
-
Nanobody-TurboID Maps the CD38 Surfaceome
2026-08-25
Feng and colleagues developed nanobody-targeted TurboID (NBID) to profile proteins positioned near CD38 on living cell surfaces. Integrated proteomics, microscopy, SILAC, and migration assays identified a CD38-associated adhesion network that links tumor-cell membrane organization with tumor–endothelial interactions.
-
Imatinib hydrochloride: Assay Workflows
2026-08-25
This scenario-based guide helps researchers interpret viability and proliferation results when using Imatinib hydrochloride, including SKU A3487, across CML and GIST models. It connects target-level potency, DMSO handling, controls, and vendor-selection criteria to practical assay decisions.
-
DiscoveryProbe™ Protease Inhibitor Library Guide
2026-08-24
A scenario-driven guide to using DiscoveryProbe™ Protease Inhibitor Library (SKU L1035) in cell viability, proliferation, cytotoxicity, and mechanistic screening workflows. It explains assay compatibility, controls, interpretation, and practical vendor-selection considerations for protease inhibition studies.
-
MK-571 (L-660,711) Assay Workflows
2026-08-24
Build cleaner inflammation experiments by separating cysteinyl leukotriene receptor signaling from ABCC1/MRP1 transport effects. This practical guide covers airway pharmacology, macrophage chemoprotection, formulation, controls, and troubleshooting for MK-571.
-
Streptozotocin Workflow for Diabetes Models
2026-08-23
Streptozotocin, or STZ, provides a practical route to reproducible pancreatic β-cell injury and experimental diabetes mellitus induction. This workflow connects model establishment with painful diabetic neuropathy assays, including microglial TBK1–pyroptosis readouts, while emphasizing formulation control and troubleshooting.
-
Gemcitabine HCl: Reliable Cytotoxicity Workflows
2026-08-22
This scenario-based guide shows how Gemcitabine HCl, SKU A1402, can support better-planned cytotoxicity, DNA replication inhibition, and pancreatic cancer studies. It connects concentration selection, solution handling, data interpretation, and MRI-guided in vivo validation without treating one assay endpoint as a substitute for another.
-
Q-VD(OMe)-OPh in Apoptosis Research
2026-08-22
Q-VD(OMe)-OPh is a broad-spectrum pan-caspase inhibitor for testing caspase dependence in apoptosis assays. The compound, also called quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone, combines recombinant-caspase potency with practical solvent and storage guidance.
-
CHI3L1-IN-5: From Target to Astrocyte Rescue
2026-08-21
CHI3L1-IN-5 (Compound Z17) is a selective CHI3L1 inhibitor that links NF-κB suppression with restoration of astrocyte amyloid clearance. This article explains the mechanistic evidence, assay logic, translational value, and practical limitations behind its use in Alzheimer’s disease research.
-
Cefepime in CNS Infection and Resistance Models
2026-08-20
Cefepime (BMY-28142) offers a useful bridge between blood-brain barrier-aware infection models and contemporary resistance research. This article outlines how translational teams can use the compound to connect exposure, bacterial killing, neurotoxicity risk, and carbapenemase-mediated transmission dynamics.
-
Sodium Picosulfate and the Gut–Liver–Brain Axis
2026-08-20
Sodium Picosulfate is best understood not only as a bowel-output reagent, but also as a controllable perturbation of intestinal water and electrolyte handling. This thought-leadership article connects its established constipation-research utility with gut–liver–brain studies, using the 2025 [18F]PBR146 neuroinflammation work as a framework while clearly separating evidence from hypothesis.
-
Anagliptin (SK-0403): DPP-4 and Vascular Research
2026-08-19
Anagliptin (SK-0403) is a potent, selective, orally active DPP-4 inhibitor reported to have an IC50 of 3.8 nM in the supplier assay. Rabbit-aorta experiments further associate its vasorelaxation with Kv channel activity and SERCA pump function, while separating those findings from clinical efficacy.
-
EPZ5676: Practical DOT1L Inhibitor Workflows
2026-08-19
EPZ5676 combines subnanomolar DOT1L potency with strong methyltransferase selectivity, making it a practical tool for linking H3K79 methylation inhibition to MLL-rearranged leukemia phenotypes. This guide covers formulation, biochemical and cellular workflows, orthogonal validation, and troubleshooting for reproducible results.
-
Gamithromycin PK/PD Cutoffs in Piglet H. parasuis
2026-08-18
Zhou et al. integrated susceptibility surveillance, serum pharmacodynamics, piglet pharmacokinetics, and population dose modeling to define epidemiological and PK/PD cutoffs for gamithromycin against Haemophilus parasuis. The study links an AUC24h/MIC exposure index to bacteriological outcomes and shows that a modest adjustment above the marketed dose could improve target attainment.